SLC5A2 and kidney disorder: The magnitude of benefit produced by SGLT2 inhibitors varied with baseline renal function, with greater reductions in hospitalizations for heart failure and smaller reductions in progression of renal disease in patients with more severe kidney disease at baseline [39].